SEARCH

SEARCH BY CITATION

References

  • Alexiou, C., Kau, R.J., Dietzfelbinger, H., Kremer, M., Spiess, J.C., Schratzenstaller, B. & Arnold, W. (1999) Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer, 85, 23052314.
  • Axelsson, U. (1986) A 20-year follow-up study of 64 subjects with M-components. Acta Medica Scandinavica, 219, 519522.
  • Axelsson, U., Bachmann, R. & Hällén, J. (1966) Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Medica Scandinavica, 179, 235247.
  • Baldini, L., Guffanti, A., Cesana, B.M., Colombi, M., Chiorboli, O. & Damilano, I. (1996) Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood, 87, 912918.
  • Bellaïche, L., Laredo, H.-D., Loité, F., Koeger, A.-C., Hamze, B., Ziza, J.-M., Pertuiset, E., Bardin, T. & Tubiana, J.-M. for the GRI Study Group (1997) Magnetic resonance appearance of monoclonal gammopathies of unknown significance and multiple myeloma. Spine, 22, 25512557.
  • Bladé, J., Lopez-Guillermo, A., Rozman, C., Cervantes, F., Salgado, C., Aguilar, J.L., Vives-Corrons, J.L. & Montserrat, E. (1992) Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 81, 391394.
  • Bladé, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 11151123.
  • Cavo, M., Galieni, P., Gobbi, M., Baldrati, L., Leardini, L., Baccarani, M. & Tura, S. (1985) Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematologica, 74, 2730.
  • Cesana, C., Klersy, C., Barbarano, L., Nosari, A.M., Crugnola, M., Pungolino, E., Gargantini, L., Granata, S., Valentini, M. & Morra, E. (2002) Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Journal of Clinical Oncology, 20, 16251634.
  • Cohen, H.J., Crawford, J., Rao, M.K., Pieper, C.F. & Currie, M.S. (1998) Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. American Journal of Medicine, 104, 439444.
  • Dimopoulos, M.A., Moulopoulos, L.A., Maniatis, A. & Alexanian, R. (2000) Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood, 96, 20372044.
  • Dispenzieri, A., Gertz, M.A., Therneau, T.M. & Kyle, R.A. (2001) Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clinic Proceedings, 76, 476487.
  • Drayson, M., Tang, L.X., Drew, R., Mead, G.P., Carr-Smith, H. & Bradwell, A.R. (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood, 97, 29002902.
  • Garcia-Sanz, R., Orfão, A., Gonzalez, M., Tabernero, M.D., Bladé, J., Moro, M.J., Fernandez-Calvo, J., Sanz, M.A., Perez-Simon, J.A., Rasillo, A. & Miguel, J.F. (1999) Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood, 93, 10321037.
  • Isaksson, E., Bjorkholm, M., Holm, G., Johansson, B., Nilsson, B., Mellstedt, H. & Osterborg, A. (1996) Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. British Journal of Haematology, 92, 7176.
  • Katzmann, J.A., Clark, R.J., Abraham, R.S., Bryant, S., Lymp, J.F., Bradwell, A.R. & Kyle, R.A. (2002) Serum reference and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chain. Clinical Chemistry, 48, 14371444.
  • Kyle, R.A. (1978) Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. American Journal of Medicine, 64, 814826.
  • Kyle, R.A. (1993) ‘Benign’ monoclonal gammopathy – after 20–35 years of follow-up. Mayo Clinic Proceedings, 68, 2636.
  • Kyle, R.A. (1999) Sequence of testing for monoclonal gammopathies. Serum and urine assays. Archives of Pathology and Laboratory Medicine, 123, 114118.
  • Kyle, R.A. & Bayrd, E.D. (1976) The Monoclonal Gammopathies: Multiple Myeloma and Related Plasma-Cell Disorders. C. C.Thomas, Springfield, IL.
  • Kyle, R.A. & Greipp, P.R. (1980) Smoldering multiple myeloma. New England Journal of Medicine, 302, 13471349.
  • Kyle, R.A. & Greipp, P.R. (1982) ‘Idiopathic’ Bence Jones proteinuria: long-term follow-up in seven patients. New England Journal of Medicine, 306, 564567.
  • Kyle, R.A., Finkelstein, S., Elveback, L.R. & Kurland, L.T. (1972) Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood, 40, 719724.
  • Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, III, L.J. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564569.
  • Liebross, R.H., Ha, C.S., Cox, J.D., Weber, D., Delasalle, K. & Alexanian, R. (1998) Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. International Journal of Radiation Oncology Biology Physics, 41, 10631067.
  • Noel, P. & Kyle, R.A. (1987) Plasma cell leukemia: an evaluation of response to therapy. American Journal of Medicine, 83, 10621068.
  • Ocqueteau, M., Orfao, A., Almeida, J., Bladé, J., Gonzalez, M., Garcia-Sanz, R., Lopez-Berges, C., Moro, M.J., Hernandez, J., Escribano, L., Caballero, D., Rozman, M. & San Miguel, J.F. (1998) Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. American Journal of Pathology, 152, 16551665.
  • Pasqualetti, P., Festuccia, V., Collacciani, A. & Casale, R. (1997) The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases. Acta Haematologica, 97, 174179.
  • Rawstron, A.C., Fenton, J.A., Ashcroft, J., English, A., Jones, R.A., Richards, S.J., Pratt, G., Owen, R., Davies, F.E., Child, J.A., Jack, A.S. & Morgan, G.J. (2000) The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood, 96, 38803886.
  • Saleun, J.P., Vicariot, M., Deroff, P. & Morin, J.F. (1982) Monoclonal gammopathies in the adult population of Finistère, France. Journal of Clinical Pathology, 35, 6368.
  • Tsang, R.W., Gospodarowicz, M.K., Pintilie, M., Bezjak, A., Wells, W., Hodgson, D.C. & Stewart, A.K. (2001) Solitary plasmacytoma treated with radiotherapy: Impact of tumor size on outcome. International Journal of Radiation Oncology Biology Physics, 50, 113120.
  • Wilder, R.B., Ha, C.S., Cox, J.D., Weber, D., Delasalle, K. & Alexanian, R. (2002) Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer, 94, 15321537.